Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Oxygen sensor study halted early – what it means for patient monitoring

NCT ID NCT07215429

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested how accurately Philips SpO2 sensors measure blood oxygen levels in 24 healthy adults aged 18-50. The sensors were compared to standard lab tests during rest. The study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help improve the accuracy of oxygen monitoring devices used in hospitals.
What could go wrong
The study was terminated early with only 24 participants, so results are limited and may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

Sep 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

minimum of 66 participants up to a maximum of 180, healthy male and female volunteers of any race, ranging in pigmentation from light to dark. he study population will meet the following stratification criteria: * At least 25% of the population with Monk 1-3 with ITA \> 30 at the forehead * At least 25% of the population with Monk 4-7 with ITA ≤ 30 and ≥ -30 at the forehead * At least 25% of the population with Monk 8-10 with ITA \< -30 at the forehead * At least half of the participants in this group will have an ITA \< -50 at the forehead * In the event the Monk and ITA place a participant in different cohorts, the ITA shall be used to determine the demographic cohort for the participant * At least 40% of the population male * At least 40% of the population female

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA Participants accepted in this study must meet all the following criteria: * Participant must have the ability to understand and provide written informed consent. * Participant is an adult between 18-50 years of age. * Participant must be willing and able to comply with study procedures and duration. * Participant is a non-smoker or who has not smoked within 2 days prior to the study. EXCLUSION CRITERIA * Participant is considered as being morbidly obese (defined as BMI \>39.5) * Compromised circulation (i.e., Raynaud's Syndrome), injury, open wound, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.) * Females who are pregnant * Females who are trying to get pregnant (with confirmation of positive urine pregnancy test unless the participant is known to be not of child-bearing potential) * Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \>3% as assessed with a Masimo Radical 7 (Rainbow) * Participants with known respiratory conditions such as: (self-reported) * uncontrolled / severe asthma, * flu, * pneumonia / bronchitis, * shortness of breath / respiratory distress, * unresolved respiratory or lung surgery, * emphysema, COPD, lung disease * Recent COVID with or without hospitalization (last 2 months) * Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) * high blood pressure: systolic \>140 mmHg or diastolic \>90 mmHg on 3 consecutive readings (reviewed during health screen) * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA) * chest pain (angina) * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen) * previous heart attack * blocked artery * unexplained shortness of breath * congestive heart failure (CHF) * history of stroke * transient ischemic attack * carotid artery disease * myocardial ischemia * myocardial infarction * cardiomyopathy * implantable active medical device such as pacemaker or automatic defibrillator * Self-reported health conditions as identified in the Health Assessment Form * diabetes, * uncontrolled thyroid disease, * kidney disease / chronic renal impairment, * history of seizures (except childhood febrile seizures), * epilepsy, * history of unexplained syncope, * recent history of frequent migraine headaches, * recent symptomatic head injury (within the last 2 months), * Cancer requiring chemotherapy, radiation, or current treatment. * Participants with known clotting disorders (self-reported) * history of bleeding disorders or personal history of prolonged bleeding from injury * history of blood clots * hemophilia * current use of blood thinner: prescription or daily use of aspirin * Sickle Cell Trait or Disease * Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) * Participants with severe allergies to iodine (only applicable if iodine is used) * Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine), * Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \<0.4) * Unwillingness or inability to remove nail polish or artificial nails from test digits. * Participant received intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring) * Surgical hardware in pathway of Device Under Test * Other known health conditions should be considered upon disclosure in health assessment form. * Participants with uneven skin tone at the sensor site or at the forehead

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulse oximetry, oxygen measurements, SPO2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Element Materials Technology

    Louisville, Colorado, 80027, United States